Endocyte Inc. (Nasdaq: ECYT) reported positive results from a Phase 2b TARGET trial of vintafolide and docetaxel in treating non-small cell lung cancer. Shares of the biopharmaceutical leaped $13.53 to close at $28.17.
Positive Results For Endocyte
March 21, 2014 at 12:17 PM EDT
